Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 2, Issue 1, 2010, Pages 35-47

  Kulkarni, Padmakar V ^a   Roney, Celeste A ^a   Antich, Peter P ^a   Bonte, Frederick J ^a   Raghu, Anjanapura V ^b   Aminabhavi, Tejraj M ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b KARNATAK UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

8-HYDROXYQUINOLINE; ALZHEIMER'S DISEASE; AMYLOID PEPTIDES; AMYLOID PLAQUES; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN DELIVERY; BRAIN TISSUE; BRAIN UPTAKE; CLIOQUINOL; CORTICAL CONTROL; CYANOACRYLATES; DELIVERY VEHICLE; EARLY DIAGNOSIS; ELDERLY PEOPLE; IMAGING AGENT; IN-VITRO; IN-VIVO; IN-VIVO IMAGING; MEDICAL DISCIPLINES; MOUSE BRAIN; NEURODEGENERATIVE DISORDERS; RESEARCH ACTIVITIES; SINGLE PHOTON EMISSION TOMOGRAPHIES; STORAGE PHOSPHORS; TRANSGENIC MICE; WILD TYPES; WILD-TYPE CONTROLS;

DIAGNOSIS; GLYCOPROTEINS; LUMINESCENCE; METAL IONS; NANOPARTICLES; PARAFFIN WAXES; PARAFFINS; PEPTIDES; PHOSPHORS; TOMOGRAPHY;

BRAIN;

2 [1 [6[(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; 5 CHLORO 7 IODO 8 HYDROXYQUINOLINE I 125; 6 IODO 2 (4' DIMETHYLAMINO)PHENYL IMIDAZO[1,2 A]PYRIDINE I 123; ALBUMIN; AMYLOID BETA PROTEIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CHITOSAN; CLIOQUINOL; COPPER; ENBUCRILATE; GELATIN; IBUPROFEN; IODINE 125; IRON; LIPOSOME; NANOPARTICLE; NAPROXEN; NIOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; PENTETATE INDIUM IN 111; PENTETREOTIDE IN 111; PHOSPHORUS; POLYANHYDRIDE; POLYCAPROLACTONE; POLYGLACTIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEM; DRUG TARGETING; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MICELLE; MOLECULAR PROBE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TRANSPORT; RADIOIODINATION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; ENBUCRILATE; HUMANS; MICE; MICE, TRANSGENIC; NANOPARTICLES; QUINOLINES;

EID: 77953666271     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.59     Document Type: Review

References (40)

1. Torchilin VP. Recent advances with liposome as pharmaceutical carriers. Nature Rev Drug Discov 2005, 2:145-160.
2. Duncan R. The dawning era of polymer therapeutics. Nature Drug Discov 2003, 2:347-360.
3. Boado RJ. Antisense drug delivery through the blood-brain barrier. Adv Drug Del Rev 1995, 15:73-107.
4. Roney CA, Kulkarni PV, Arora V, Antich P, Bonte F, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005, 108:193-214.
5. Gutman R, Peacock G, Lu D. Targeted drug delivery for brain cancer treatment. J Control Release 2000, 65:31-41.
6. Zhuang Z. Radio-iodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001, 44:1905-1914.
7. Smith, Q A review of blood brain barrier transport techniques. The Blood Brain Barrier: Biology and Research Protocols, ed. S Sag. Vol. 89. 2003, Totowa, NJ: Humana Press, Inc. 193-205.
8. Huang X. The AB peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38:7609-7616.
9. Ritchie C.Metal-protein attenuation with iodochlorhydorxyquin (clioquinol) targeting AB amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 2003, 60:1685-1691.
10. Mundargi RC, Ramesh Babu V, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release 2008, 125:193-209.
11. Wang G, Uludag H. Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opin Drug Delivery 2008, 5:499-515.
12. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70:1-20.
13. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999, 16:1564-1569.
14. Ḧartig W, Paulke BR, Varga C, Seeger J, Harkany T, et al. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer's disease. Neurosci Lett 2003, 338:174-176.
15. Siegemund T, Paulke BR, Schmiedel H, Bordag N, Hoffmann A, et al. Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice. Int J Dev Neurosci 2006, 24:195-201.
16. Barnabas W, Kumar SM, Kumaraswamy S, Kokilampal PSK, Nallupillai P, et al. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008, 1200:159-168.
17. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008, 70:75-84.
18. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002, 28:1-13.
19. Calvo P, Gouritin V, Chacun H, Desmaele D, D'Angelo J, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001, 18:1157-1166.
20. Reddy JS, Venkateswarlu V. Novel delivery systems for drug targeting to the brain. Drugs Future 2004, 29:63-69.
21. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol 2004, 4:484-488.
22. Koo YEL, Reddy GR, Bhojani M, Schneider R, Philbert MA, et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006, 58:1556-1577.
23. Lovell M. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998, 158:47-52.
24. Suh SW. Histological evidence implicating zinc in Alzheimer's disease. Brain Res 2000, 852:274-278.
25. Cherney RA. Treatment with a copper-zinc chelator markedly and ragidly inhibits B-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
26. Yassin MS. Changes in uptake of vitamin B (12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 2000, 173:40-44.
27. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 2002, 23: 1031-1038.
28. Kontush A. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001, 30:119-128.
29. Teixido M, Giralt E. The role of peptides in bloodbrain barrier nanotechnology. J Peptide Sci 2008, 14:163-173.
30. De Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinetics 2007, 46:553-576.
31. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood brain barrier with collodial polymer particles (nanoparticles). Brain Res 1995, 674:171-174.
32. Klunk WE. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001, 69:1471-1484.
33. Ahi J, Radulovic J, Spiess J. The role of hippocampal signaling cascades in consolidation of fear memory. Behav Brain Res 2004, 149:17-31.
34. Blank T. Priming of long-term potentiation in mouse hippocampus by corticotropin-releasing factor and acute stress: implications for hippocampus-dependent learning. J Neurosci 2002, 22:3788-3794.
35. 2+ complexes in Alzheimer's disease. Aging Cell 2006, 5:69-79.
36. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, et al. 2-Dialkylaminoa-6-acylmalononitrile substituted naphthelnes (DDNP analog): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 2003, 5:404-417.
37. 123I-IMP: A novel Amyloid plaque-Imaging Agent for the Diagnosis of Alzheimer's Disease. J Nucl Med 2006, 47:748-754.
38. Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 1996, 706:181-193.
39. Cattaneo A, Capsoni S, Paoletti F. Towards non invasive nerve growth factor therapies for Alzheimer's disease. J Alzheimers Dis 2008, 15:255-283.
40. Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, et al. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res 2008, 25:2674-2684.